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Signal transduction via G-protein-coupled receptors (GPCRs) is a fundamental pathway through which the functions of an individual cell can be
integrated within the demands of a multicellular organism. Since this family of receptors first discovered, the proteins that constitute this signaling
cascade and their interactions with one another have been studied intensely. In parallel, the pivotal role of lipids in the correct and efficient
propagation of extracellular signals has attracted ever increasing attention. This is not surprising given that most of the signal transduction machinery
is membrane-associated and therefore lipid-related. Hence, lipid–protein interactions exert a considerable influence on the activity of these proteins.
This review focuses on the post-translational lipid modifications of GPCRs and G proteins (palmitoylation, myristoylation, and isoprenylation) and
their significance for membrane binding, trafficking and signaling. Moreover, we address how the particular biophysical properties of different
membrane structures may regulate the localization of these proteins and the potential functional consequences of this phenomenon in signal
transduction. Finally, the interactions that occur between membrane lipids and GPCR effector enzymes such as PLC and PKC are also considered.
© 2006 Elsevier B.V. All rights reserved.Keywords: Signal transduction; Membrane structure; G-protein-coupled receptor; G protein; Palmitoylation; Myristoylation; Isoprenylation; Farnesyl;
Geranylgeraniol; Phospholipase C; Protein kinase C
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Biological membranes are vital components of living
organisms, providing a diffusion barrier that separates cells
from the extracellular environment or which compartmentalizes
specialized organelles within the cell. The lipid bilayer of
membranes hinders the free diffusion of ions, a prerequisite to
create electrochemical potentials that can be used for the
synthesis of ATP or for active transport. Beside this general
purpose of biological membranes, the interaction of lipids and
membrane proteins impinges on basic biochemical processes
between the separated areas on both sides of the membrane,
such as respiration, photosynthesis, protein and solute transport,
motility, and signal transduction. The importance of these
proteins is underlined by the fact, that the proportion of putative
membrane proteins predicted from the sequenced human
genome is around 30% [1]. In order to maintain the diffusion
barrier and to keep it electrochemically sealed, a close
interaction of membrane proteins with the lipid bilayer is
obligatory. This is especially important given that many
membrane proteins undergo conformational changes that affect
their transmembrane regions and that may regulate their
activity, as seen for G-protein-coupled receptors (GPCRs) and
G proteins [2–4]. The lateral and rotational mobility of
membrane lipids supports the sealing function while allowing
a structural rearrangement of membrane proteins, because they
can adhere to the surface of integral membrane proteins and
flexibly adjust to a changing microenvironment. In this context,
different membrane proteins are selective for certain phospho-
lipids [5] and likewise particular phospholipids are essential for
the activity of certain membrane proteins [6]. However, in most
cases the basis underlying the specific lipid requirements of
membrane components remains unclear.
One special kind of lipid–protein interaction that participates
in G-protein-associated signaling involves well-known co- or
post-translational lipid modifications of the majority of
signaling proteins (myristoylation, palmitoylation and isopre-
nylation). These modifications are particularly prevalent in
integral or peripheral membrane proteins, such as GPCRs, G
proteins, G-protein-coupled effector enzymes and receptor
kinases [7–10]. Protein lipidation is the first important lipid–
protein interaction that occurs in GPCR-related signaling, and it
includes the covalent binding of a hydrophobic lipid molecule
to the signaling protein. The other important kind of lipid–
protein interaction is the influence of plasma membrane lipids
and their membrane organization on signaling proteins, andconsequently on signal transduction. In this context, the lipid–
protein interaction is mediated by the chemical nature of the
lipids and the resulting biophysical properties of the membrane
in which they are inserted. By these means, membrane lipids are
not only involved in the trafficking of newly synthesized
proteins to the plasma membrane and their lateral distribution
within it, but they also modulate their enzymatic activity. The
chemical properties of lipids can also lead to the segregation of
specific membrane regions into microdomains, a phenomenon
that also seems to be implicated in signal transduction,
membrane transport, and protein sorting [11,12]. However,
the fact that the influence between membrane lipids and proteins
is not unilateral and that can occur in both directions is often
overlooked. This means that integral and peripheral proteins are
able to perturb their immediate lipid environment (e.g., to
facilitate or inhibit the chain and translational ordering of
adjacent phospholipids), thereby modifying plasma membrane
properties and organization [13,14]. Taken together, the variety
of interactions between membrane lipids and proteins reflects
the complexity of their relationship and the multitude of
possible regulatory processes involved in GPCR-associated
signal transduction.
2. Lipid modifications of GPCRs
GPCRs form by far the largest family of cell surface proteins
involved in signaling across biological membranes. Indeed,
within the human genome approximately 950 genes encode
proteins of this superfamily [15]. Hence, the wide diversity of
the possible agonists and the factors that may modulate
signaling, coupled with the widespread distribution of these
receptors enables GPCRs to be employed in the physiological
regulation of virtually all biological activities.
2.1. Fatty acylation of GPCRs
GPCRs are integral plasma membrane proteins that contain
seven membrane-spanning domains, connected by three extra-
cellular and intracellular loops. Therefore, in contrast to
peripheral proteins that depend on fatty acylation for tight
membrane attachment (e.g., G proteins, see Section 3), GPCRs
do not need any kind of co- or post-translational lipid
modification to ensure proper membrane binding. Never-
theless, GPCRs are also subject to lipid modifications. While
the most frequent lipid modifications of proteins are generally
N-myristoylation, isoprenylation and thio(S)-acylation, as a rule
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attachment of palmitate to one or more cysteine residues via a
thioester bond. The exact site is typically a cysteine residue in the
cytoplasmic tail of the protein, positioned 10 to 14 amino acids
downstream of the last transmembrane domain (i.e., close to the
carboxy terminus of the receptor [16]). Rhodopsin was the first
GPCR to be identified as a target for palmitoylation [7], and it
was suggested that the attached palmitate might be incorporated
into the plasmamembrane bilayer, thereby creating an additional
intracellular loop. This was later corroborated by the use of
fluorescent fatty acid analogues [17]. As a consequence,
palmitoylation has a profound effect on the local conformation
of this domain, and it possibly controls the interaction of GPCRs
with specific regulatory proteins. When the palmitoylation of the
β2-adrenergic receptor was characterized, the palmitoylated
cysteine was again found in the carboxy terminal tail of the
protein at an analogous position to that in rhodopsin [18].
Moreover, cysteine residues at similar locations were found in
about 80% of all GPCRs (Table 1), indicating that palmitoylation
is a general characteristic of this type of receptor. However,
GPCR palmitoylation may not be restricted to the carboxy
terminal of the receptor. Indeed, when all cysteines in the
carboxyl tail of the rat μ-opioid receptor were mutated there was
no effect on palmitate incorporation [19], suggesting that
palmitoylation sites exist outside of this receptor domain.
Further evidence of other palmitoylation sites, even in receptors
that are palmitoylated in their carboxy terminal tail, came from
studies of the V1a vasopressin receptor [20]. In this case,
mutations of the cysteines in the carboxyl tail did not completely
eliminate palmitoylation, suggesting the presence of palmitoy-
lated cysteines in the intracellular loops that connect the
transmembrane spans.
Beside palmitoylation, the only other lipid modification of
GPCRs identified is the isoprenylation of the prostacyclinTable 1
Palmitoylation dependence for G protein coupling
Cysteines
GPCRs with palmitoylation-dependent G protein coupling
Bovine rhodopsin 322, 323
Human β2-adrenergic receptor 341
Human M2 muscarinic acetylcholine
receptor
457
Human somatostatin receptor, type 5 320
Human endothelin receptor, subtype A, ETA 383, 385–38
Human endothelin receptor, subtype B, ETB 402, 403, 40
[+ Cys 400]
Human prostacyclin receptor, IP 308, 311 383
GPCRs w/o palmitoylation-dependent G protein coupling
Porcine α2A-adrenergic receptor 442
Rat LH/hCG receptor 621, 622
Human dopamine D1 receptor 347, 351
Human adenosine A1 receptor 309
Human thyrotropin receptor 699
a Bold cysteine residues represent sites for thioester-linked palmitoylation, as iden
b Palmitoylated cysteine residues were detected by mass spectrometry.
c Bold, underlined cysteine residue represents site for thioether-linked isoprenylatreceptor. The prostacyclin receptor from a number of species
contains an identical conserved putative isoprenylation CaaX
motif in the carboxy terminal tail that corresponds to the
sequence CSLC. Indeed, it was shown that the human
prostacyclin receptor is C-15 farnesylated on Cys383 in its
carboxy terminal tail and that it is also palmitoylated on Cys308
and 311 [21,22]. Dual lipidation via palmitoylation and
isoprenylation, is not unique to the prostacyclin receptor as it
occurs in a variety of different proteins (e.g., RhoB, Ha-Ras and
N-Ras: [23,24]). Palmitoylation of isoprenylated proteins
generally takes place at membranes whereby isoprenylation
precedes palmitoylation [25]. In general, a second lipid
modification may serve to further augment the hydrophobicity
of the protein and consequently increase its membrane affinity,
converting the affected proteins into permanent residents of the
membrane. Nevertheless, since palmitoylation occurs after
isoprenylation, the first signal may also be required to permit
an initial interaction with membranes thereby facilitating
palmitoylation by a membrane-bound palmitoyltransferase
[26,27], a process that else would be unable to occur.
2.2. Role of lipid modifications in GPCR trafficking
In contrast to other lipid modifications, palmitoylation is a
very dynamic modification. The acyl-thioester bond attaching
the 16-carbon saturated palmitate moiety to the specific cysteine
residues of its target protein is chemically labile and it has been
shown to be rapidly turned over [28–30]. This rapid turnover
suggests that palmitoylation/depalmitoylation may exert a
regulatory influence on protein function. However, when
considering possible functional roles of palmitoylation, it is
important to differentiate between constitutive and dynamic
palmitoylation. In this context, constitutive palmitoylation
refers to the first protein acylation that occurs during or shortlyReference Selected sites of modification a
[201] QFRNCMVTTLCCGKNPLGDDEA
[18] DFRIAFQELLCLRRSSLKAYG
[202] KKTFKHLLMCHYKNIGATR
[203] DNFRQSFQKVLCRLKGSGAKDADA
8 [204] [205] KFKNCFQSCLCCCCYSKSLMTSV
5 [53] [205] RFKNCFKSCLCCWCQSFEEKQSLE
RFKNCFKSCLCCWCQSFEEKQSLEb
[22] [21] AVFQRLKLWVCCLCLGPAHGDSQTP
SAVGTSSKAEASVACSLCc
[52] HDFRRAFKKILCRGDRKRIV
[206] DFLLLLSRFGCCKRRAELYRRK
[207] RKAFSTLLGCYRLCPATNNAIETV
[58] FLKIWNDHFRCQPAPPIDEDL
[208] VFILLSKFGICKRQAQAYRGQ
tified by mutagenesis.
ion as identified by mutagenesis.
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corresponds to the regulation of the palmitoylation state of the
mature protein once it has reached its specific location. It is
recommendable to define these differences, since there is strong
evidence that GPCR palmitoylation may be implicated in the
efficient expression of the functional receptor at the cell surface.
Thus, palmitoylation could fulfill two different roles: the
processing and targeting of the protein to the correct membrane
site and independently, a signaling function in the final receptor.
This is consistent with the fact that palmitoylation of membrane
proteins has been detected in several cellular locations.
Accordingly, palmitoylation of caveolin-1 [31] and of the
transferrin receptor [32] appears to take place at the plasma
membrane, whereas the palmitoylation of viral polypeptides
and glycoproteins seems to occur in the Golgi [33,34]. Other
proteins are palmitoylated even earlier in their biosynthetic
pathway (i.e., in the endoplasmic reticulum [35]). It is difficult
to corroborate whether all of these locations are true sites of
palmitoylation or whether the results only reflect the rapid
intracellular movement of the corresponding proteins. Never-
theless, it is possible that a single membrane protein could be
modified at various sites in the cell during its lifespan. In this
context, the δ-opioid receptor has recently been shown to be
palmitoylated during or shortly after export from the endoplas-
mic reticulum [36]. Blockage of this palmitoylation inhibited
the cell surface expression of the receptor implying that this
lipid modification is crucial for its correct intracellular
trafficking. In the same study the δ-opioid receptor was also
shown to be palmitoylated at the plasma membrane, and that the
palmitoylation turnover in this domain is dependent on receptor
activation by agonist. More evidence indicating that other
GPCRs are processed in the same way was contributed by
several studies demonstrating an intracellular accumulation of
the receptor, when its specific palmitoylation sites were
mutated. This was the case for bovine opsin [37], the
lutropin/choriogonadotropin receptor [38], the H2 histamine
receptor [39], and the chemokine CCR5 receptor [40].
Intracellular receptor retention upon mutating the two specific
palmitoylated cysteines (Cys341 and Cys342) was also reported
for the vasopressin V2 receptor [41], although palmitoylation of
only one of these cysteines was sufficient to completely restore
cell surface expression of the receptor [42].
2.3. The role of lipid modifications in GPCR signaling
The fact that palmitic acid turns over more rapidly than the
half-life of the protein [43,44] supports the idea that palmitoyla-
tion, like phosphorylation, is likely to be a regulatory mechanism
in the cell [45]. Accordingly, an increase in palmitate turnover
can be provoked in response to extracellular stimuli [46]. Indeed,
for a variety of GPCRs, such as the β2-adrenergic and α2A-
adrenergic receptor, the palmitoylation/depalmitoylation cycle is
activation-dependent [20,47–51]. However, when considering
the effect of GPCR palmitoylation on G protein coupling the
situation is somewhat less clear (Table 1). While receptors like
the β2-adrenergic receptor are uncoupled from their correspond-
ing G protein upon mutagenesis of their palmitoylation site [18],the signaling of others like the α2A-adrenergic receptor is not
significantly affected by this modification [52]. In some cases,
the elimination of specific palmitoylated cysteines seems to
exert a different influence on G protein coupling in terms of the
type of G protein α subunit (Gα) with which the receptor may
associate. For example, the loss of all palmitoylation sites
(Cys402, Cys403 and Cys405) from the endothelin receptor
subtype B abolishes receptor coupling with Gαq and Gαi. When
Cys402 alone is restored, the receptor can couple with Gαq but
not Gαi, the latter clearly requiring the more palmitoylation sites
available to interact accurately with the receptor [53]. The reason
for the uncoupling of some GPCRs and the loss of downstream
signaling could be due to enhanced receptor phosphorylation in
the absence of palmitoylation. Indeed, the phosphorylated amino
acids of GPCRs are in close vicinity to the sites of palmitoyla-
tion. In this context, the unstimulated β2-adrenergic receptor
mutant is already hyperphosphorylated and even in the presence
of its agonist isoproterenol, it does not undergo further
phosphorylation [54]. Phosphorylation is the first step of
receptor desensitization and it initiates receptor uncoupling
from the interacting G protein. Consequently, it has been
recently shown in transgenic knock-in mice expressing a
palmitoylation-deficient rhodopsin that this mutation facilitated
receptor phosphorylation leading to an increased shutoff of
phototransduction upon stimulation [55]. Thus, receptor palmi-
toylation is believed to regulate the access to phosphorylation
sites in the receptor, thereby inhibiting rapid desensitization.
Phosphorylation of GPCRs usually initiates their internalization,
an event that terminates in protein degradation (down-regula-
tion) or receptor recycling to the cell surface (resensitization).
Accordingly, phosphorylation, desensitization and internaliza-
tion were enhanced in a palmitoylation-deficient mutant of the 5-
HT4a hydroxytryptamine and the luteinizing hormone receptor,
further supporting the relevance of receptor palmitoylation as a
regulator of GPCR-mediated signal transduction [56,57].
Nevertheless, great care must be taken when interpreting
results from experiments carried out with proteins containing
mutated cysteine residues. The free sulfhydryl (-SH) group of
the specific unpalmitoylated cysteine residue may also be
responsible for other important interactions apart from possible
modification by lipid attachment. Free sulfhydryl groups can
form hydrogen or disulfide bonds that may be vital to maintain
specific protein configurations in the absence of the palmitate
residue. The mutation of the cysteine in these motifs would also
affect these structural considerations. In this context, the
drastically different half-lives of the wild-type and cysteine-
mutated human A1 adenosine receptor [58] may be attributed
either to the loss of palmitoylation as such or to the enhanced
degradation due to the misfolded tertiary protein structure of the
unpalmitoylated protein.
3. Lipid modifications of heterotrimeric G proteins
Heterotrimeric G proteins (αβγ), like many signaling
proteins, bind tightly, and often reversibly, to cellular
membranes. Covalent lipid modifications mediate membrane
binding of these peripheral membrane proteins by serving as
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their N-termini by the fatty acids myristate and/or palmitate,
while γ subunits of βγ dimers (Gβγ) are modified by farnesyl
or geranylgeranyl isoprenoids at their C-termini (Table 2).
3.1. Fatty acylation of Gα subunits
Myristoylation occurs exclusively on Gα of the αi family
[59,60]. As is the case with all myristoylated proteins, an N-
myristoyltransferase catalyzes the amide bond attachment of the
14-carbon saturated fatty acid myristate to the extreme N-
terminus of a protein [61]. This modification occurs co-
translationally and requires a glycine at the extreme N-terminus
of a substrate protein; thus, a prerequisite is removal of the
initiating methionine by a methionyl amino peptidase. Not all
extreme N-terminal glycines, however, are myristoylated, since
the N-myristoyltransferase displays a strong preference for
specific amino acids following the glycine. For example, αs is
not myristoylated even though it possesses a glycine at position
2. Most evidence indicates that myristoylation is an irreversible
modification. Interestingly, αt, also known as transducin, is
found as a mixture in which the protein is modified by myristate
or one of three less hydrophobic fatty acids; however, this
diversity of modification at the N-terminal glycine appears to be
retina specific [62,63].
All mammalian Gα, with the exception of αt and αgust
undergo palmitoylation [59,60]. The 16-carbon palmitate is
linked post-translationally via a thioester bond to one or moreTable 2
Lipid modifications of heterotrimeric G proteins
Gα Lipid modification Selected sites of modification a
αs, αolf Palmitoylation and
N-palmitoylation b
αs MGCLGNSKT-
αq, α11, α14, α16 Palmitoylation
(2 or more sites)
αq MTLESIMACCLSEEA-α16
MARSLRWRCCPWCL- c
αi1, αi2, αi3, αo, αz Myristoylation and
palmitoylation
αi1 MGCTLSAED-
αt1, αt2, αgust Myristoylation αi1 MGAGASAEE-
α12, α13 Palmitoylation
(α12=1 site;
α13=2 sites)
α12 MSGVVRTLSRCLLPAE-
α13 MADFLPSRSVLSVCFPGCV-
Gγ Lipid modification d Selected sites of modification e
γ1, γ9, γ11 Farnesylation γ1-KNPFKELKGGCVIS
γ2, γ3, γ4, γ5, γ7,
γ8, γ10, γ12, γ13
Geranylgeranylation γ2-ENPFREKKFFCAIL
a Shown are selected extreme N-termini of Gα. Underlined glycine residues
represent sites for N-myristoylation or N-palmitoylation (for αs) after removal of
the initiating methionine. Bold cysteine residues represent sites for thioester-
linked palmitoylation, as identified bymutagenesis and palmitate labeling studies.
b N-terminal palmitoylation has not been tested for αolf.
c Bold cysteine residues represent probable sites for palmitoylation of α16;
however, mutagenesis of these cysteines has not yet been reported.
d Although all mammalian Gγ are modified by a single isoprenyl group, the S.
cerevisiaeGγ, Ste18, is modified by both farnesylation and palmitoylation at the
C-terminus.
e Shown are selected extreme C-termini of Gγ. Bold cysteine residues
represent sites for isoprenylation. Underlined residues indicate the three amino
acids removed by a CaaX protease.cysteines within the first 20 N-terminal amino acids of Gα. αi
Family members thus contain a tandem myristoylation plus
palmitoylation motif, while other Gα are only palmitoylated.
No clear recognition motif has been identified for palmitoyla-
tion, although the presence of an initial membrane targeting
signal, for example myristoylation in the case of αi or
interaction with Gβγ in the case of non-myristoylated Gα,
often serves as a prerequisite. Although a palmitoyltransferase
has not yet been clearly identified for Gα, bona fide
palmitoyltransferases have very recently been identified for
several proteins, including yeast and mammalian Ras [64].
These identified palmitoyltransferases are members of a large
family of proteins, and thus it appears likely that a relevant
palmitoyltransferase will soon be identified for Gα.
Although palmitoylation generally occurs on cysteine
residues, a recent report demonstrated that a purified preparation
of αs contained palmitate covalently attached to the N-terminal
glycine through an amide bond [65]. This raises the intriguing
possibility that αs, at least under certain conditions, might be
modified by dual palmitoylation, one through an amide linkage
on glycine 2 and one through a thioester linkage on cysteine 3.
This would be somewhat analogous to the dual myristoylation
and palmitoylation of the αi family of subunits. However, no
enzyme activity responsible for such amide linked palmitoyla-
tion has been identified, and the functional significance of
N-terminal palmitoylation of αs has not yet been addressed.
One particularly important aspect of palmitoylation is that it
is a reversible modification, and indeed regulation of palmi-
toylation has been demonstrated for Gα [66]. G-protein-coupled
receptor (GPCR)-mediated activation of Gα causes an increased
rate of turnover of the attached palmitate, as measured through
pulse-chase labeling studies using radiolabeled palmitate. This
has been most clearly demonstrated for αs, but activation-
induced palmitate turnover has also been shown for several
other Gα, suggesting that regulation of the state of palmitoyla-
tion of Gα by GPCR-mediated activation is a general
phenomenon. For αs, it has been demonstrated that activation
causes a reversible translocation from the plasma membrane
into the cell's cytoplasm [67–70]. This correlation between
depalmitoylation and redistribution of αs suggests a causative
relationship, although this mechanism still remains to be
confirmed. Changes in palmitoylation can clearly affect the
subcellular localization and trafficking of αs, or other Gα, but
understanding the functional significance of such regulated
changes in localization is a current challenge.
3.2. Isoprenylation of Gγ subunits
All 12 mammalian G protein γ subunits are isoprenylated
[71], meaning thioether attachment of either the 20 carbon
geranylgeranyl or 15 carbon farnesyl moiety to a C-terminal
cysteine in a CaaX motif, in which the cysteine is followed
by two aliphatic amino acids and the X amino acid that
specifies recognition by either well-characterized geranylger-
anyl or farnesyl transferases. Most γ subunits are geranylger-
anylated, but γ1 (retina specific), γ9, and γ11 are modified
by farnesylation. After irreversible isoprenylation, most
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tions of proteolysis of the C-terminal three -aaX residues and
then carboxy methylation of the new isoprenylcysteine C-
terminus [72]. Though recognized for many years, the role of
these two subsequent modifications is surprisingly still not clear;
however, carboxy methylation does appear to increase mem-
brane binding of farnesylated proteins, most likely by a general
increase in hydrophobicity. On the other hand, the greater
hydrophobicity of the geranylgeranyl lipid compared to farnesyl
makes it a strong membrane anchor that does not seem to require
methylation to increase strength of membrane binding.
3.3. Role of lipid modifications in G protein membrane
binding, trafficking and signaling
It is clear that a major role for lipid modifications of G
proteins is to serve as hydrophobic membrane anchors for
attachment of the proteins to the cytoplasmic face of cellular
membranes, presumably by direct insertion of the attached lipid
into a lipid bilayer. Consistent with this, a number of studies
have shown that mutation of the lipid acceptor amino acid (e.g.,
Gly to Ala for myristoylated Gα, or Cys to Ser for palmitoylated
Gα or isoprenylated Gγ) to prevent modification causes the G
protein subunit to redistribute from being tightly attached to
cellular membranes to being cytoplasmic/soluble, as measured
by cell fractionation or immunofluorescence microscopy.
Moreover, lipid modification of G proteins is essential for
them to carry out their signaling functions. The simplest
explanation is that G proteins must be stably anchored at plasma
membranes to transmit signals, and thus G proteins that are not
lipid modified show signaling defects simply because they
cannot get to the proper membrane location. However,
additional roles for the various lipid modifications are possible,
and recent studies have suggested that myristoylation is critical
for maintaining N-terminal structure of αt [73] and that the
isoprenyl group of Gγ can bind to a hydrophobic pocket in Gβ
under certain circumstances [74].
Not only do lipid modifications of G proteins allow tight
membrane binding of G proteins, they play a critical role in
trafficking of G proteins to the plasma membrane. Recent
studies on heterotrimeric G proteins [75–77] combined with a
number of groundbreaking studies on lipid-modified small
GTPases of the Ras family [78] have led to a working model for
how G proteins transit to the plasma membrane after synthesis.
After isoprenylation of the Gγ subunit of the Gβγ dimer by a
cytosolic farnesyl or geranylgeranyl transferase, Gβγ localizes
to the cytoplasmic face of the endoplasmic reticulum (ER)
where the subsequent processing enzymes, Rce (the -aaX
protease) and Icmt (isoprenyl carboxy methyltransferase) are
located. Isoprenylated proteins appear to require a second
membrane targeting signal, such as palmitoylation, to proceed
from the ER to plasma membranes, but Gβγ contains no
obvious membrane targeting signals other than isoprenylation.
Thus, interaction of Gβγ with a Gα subunit to form a
heterotrimer before reaching the plasma membrane would
provide palmitoylation (and myristoylation in the case of αi
subunits) in trans as an additional membrane targeting signal.Consistent with this proposal of heterotrimer formation before
reaching the plasma membrane, mutational studies have
demonstrated a reciprocal requirement for Gα and Gβγ
interacting with each other for proper plasma membrane
localization [76,79,80]. The exact intracellular localization
where Gα and Gβγ interact is not clear; one study suggested
that αi and βγ first interact at the Golgi and proposed that this is
also where palmitoylation would occur [75]. However, other
studies have shown that disruption of the Golgi by treatment
with brefeldin A did not affect palmitoylation or plasma
membrane localization of several Gα [77,81,82]. Golgi-
independent transport thus suggests that Gα and Gβγ may
interact at ER membranes. Nonetheless, the location(s) at which
Gα undergo post-translational palmitoylation remains unde-
fined. The exact pathway the G proteins take when trafficking
from the ER to the plasma membrane also remains unresolved.
4. Membrane lipids and their relevance for GPCR-related
signaling
If the only purpose of membranes were to form a molecular
barrier and a support for proteins, then two simple lipids such as
phosphatidylcholine (PC) and cholesterol would be sufficient to
produce a selective and consistent lipid bilayer. However, this
rather passive view of the membrane has had to be revised
owing to recent discoveries showing that membrane lipids are
involved in crucial cell functions. This more active role justifies
the presence of the multitude of different lipid classes and
species found in biological membranes.
4.1. The modern membrane model
The diverse lipid species that can be encountered in the
different cell membranes and the precise regulation of their
composition reflects their significant role in cell physiology. For
example, the numerous organelles within a cell have discrete
membranes, each with a unique lipid composition and some
containing specific lipid species [83,84]. Indeed, even within an
single membrane, the exoplasmic and cytoplasmic leaflets can
display quite different lipid compositions [85–87]. Conse-
quently, membranes are far more organized than was initially
believed. Clearly, the image of the membrane as a simple
accumulation of bipolar lipid molecules in a liquid crystalline
state with total lateral and rotational freedom, and with a
random distribution of its molecular components is now
outdated. Over and above the heterogeneity in the membrane
lipid composition already illustrated, the existence of micro-
domains adds a further complexity to these structures. Certain
areas within a given membrane (e.g., lipid rafts, pre- and
postsynaptical membrane areas, basal, apical and lateral regions
of epithelial cells, etc.) have a defined lipid composition that
diverges significantly from other regions of the same cell
membrane. These domains coexist in a single membrane
without intermixing their lipid components and as such, they
maintain their own special biophysical properties and are
enriched in certain membrane proteins [88]. The resulting
mosaic structure of the membrane may be stable over long
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membranes. Alternatively, they may be more dynamic and
volatile as is the case of lipid rafts [89]. Thus, it is clear that such
precisely regulated membrane lipid distribution contradicts the
classical view of the membrane as a mere support for proteins.
As a result, a more complex membrane model has been
proposed to encompass these findings, namely the dynamically
structured mosaic model, which highlights the non-random
distribution of specific membrane lipids and proteins [90].
4.2. Membrane structures
Cellular lipids usually assemble in the form of lipid bilayers,
also known as lamellar lipid phases, and to date several subtypes
of lamellar structures have been described. Themost abundant of
these structures is the Lα or liquid crystalline phase, character-
ized by the high mobility of the fatty acid moieties in the central
hydrophobic region of the bilayer. Indeed, this organization
essentially represents the fluid membrane state that Singer and
Nicolson described in the early seventies [91]. However, under
different conditions lamellar bilayers organize into more ordered
states, such as the Lβ (gel), Lc (pseudo-crystalline) or Pβ'
(rippled) membrane state [92]. A special subtype of the lamellar
membrane phase, the lo (liquid-ordered) phase, has been
examined intensely over the last decade since it existence was
first predicted [93]. Today it is generally accepted that this phase
represents a real plasma membrane microdomain known as the
lipid raft, which fulfils an important role in signal transduction
[88]. The lo phase is characterized by the tight packing of the
extended acyl chains of lipids, as in the gel phase, while it still
maintains a certain degree of lateral mobility [94]. In contrast,
membranes with high levels of non-lamellar prone lipids have
different physical properties. In these non-lamellar membranes
the acyl chains are more loosely packed and the lipids only apply
weak lateral pressure on the polar regions of the membrane, the
reason why they are also referred to as frustrated (Lε)
membranes. This low lateral surface pressure can lead to a
splayed configuration of some phospholipids, whereby one of
the phospholipid acyl chains extends out of the bilayer while the
other remains within the membrane [95]. In vitro, lipid curvature
stress dominates the organization of lipids into hexagonal or
inverted hexagonal phases (HI or HII, respectively), cubic phases
(discontinous, or micellar, and bicontinuous) and rhombohedral
phases [92]. The presence of real non-lamellar structures in vivo
is not very frequent and they are typically restricted to membrane
conditions with extreme curvature like vesicle fission during
endo- and exocytosis [96] or cell division [97]. However, the
membrane propensity to adopt these structures is also associated
with important cellular functions, especially G-protein-coupled
signaling.
4.3. Lipid–protein interactions between membrane lipids,
GPCRs and G proteins
We must also bear in mind that the post- or co-translational
lipid modifications of GPCRs and G proteins described above
only constitute one side of the story. In this case, the nature ofthe lipid moiety attached dictates the specific requirements of
the optimal membrane lipid environment necessary for the
correct localization and function of these signaling proteins. It is
obvious that the association of both GPCRs and G proteins to
the plasma membrane makes them susceptible to their lipid
environment, such that lipid–protein interactions may be critical
to protein function. However in turn, these proteins are also
capable of modulating lipid structure and the organization of the
membrane with which they interact.
4.3.1. Membrane fluidity
Membrane fluidity, or the reciprocal value microviscosity,
was one of the first properties of membranes shown to influence
the activity of important proteins [98]. Since then, many studies
have set out to elucidate the relationship between GPCR
function and the biophysical properties of membranes in terms
of bilayer viscosity. Membrane fluidity depends on the lipid
composition of the membrane, especially on the type of fatty
acid moieties in the membrane phospholipids and the amount of
cholesterol. As a rule of thumb, a high degree of unsaturation in
the phospholipid fatty acids increases the fluidity of the
membrane [99]. For this reason, alterations in lipid composition
provoked by metabolic disorders or nutritional interventions can
affect membrane fluidity [100,101]. Indeed, diseases in which
GPCR-mediated signaling plays an important role, such as
hypertension and Alzheimer disease, have been associated with
altered membrane fluidity [102–105]. Decreased membrane
fluidity was detected in different cell types of spontaneously
hypertensive rats [106] and hypertensive patients [107]. These
changes not only restricted rotational mobility, but they also
affected lateral diffusion in the membrane of genetically
hypertensive animals [108]. Moreover, Gurdal and coworkers
found a correlation between low membrane fluidity and
impaired coupling of αs with the β2-adrenergic receptor,
which mediates vasorelaxation and as a result reduction of
blood pressure, in aortas of rats [109]. In contrast, another study
carried out in crude membrane preparations from rat lung
showed the opposite relationship, concluding that the age-
related alteration in coupling between the receptor and the
G protein is difficult to explain by alterations in membrane
fluidity [110]. However, membrane fluidity is a general
biophysical parameter that only broadly characterizes mem-
brane properties. It does not distinguish between the properties
of distinct membrane areas and as such it is fundamentally
based on the traditional Singer-Nicolson model that envisages
the plasma membrane as a unique, uniform structure. There-
fore, perhaps the measurement of membrane fluidity has lost
some of its scientific interest in recent years, although
alterations of this parameter obviously indicate (albeit not in
detail) changes in the status of membrane lipids.
4.3.2. Interaction of membrane lipids with GPCRs and G
proteins
The binding of an agonist activates GPCRs by inducing a
conformational change in protein structure that leads to the
activation of heterotrimeric G proteins. Subsequently, the Gα-
subunit of the heterotrimeric complex exchanges bound GDP
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molecular entities to regulate the activity of their specific
effectors. A general feature of this receptor-mediated signaling
pathway is that it operates as a signal amplification cascade, the
first amplification step occurring at the plasma membrane where
a signal propagated from a GPCR activates numerous G
proteins. Hence, it would be advantageous if a large number of
inactive heterotrimeric G protein molecules were readily
available in the proximity of the receptor. Indeed, the results
of an early study of signal transduction kinetics in human
platelet membranes suggested that about one third of the α 2-
adrenergic receptors seem to be coupled to αi prior to agonist
binding [111]. However, while the protein–lipid interactions
between G proteins and lamellar membranes have been
comprehensively studied [112], much less attention has been
paid to the potential interactions with non-lamellar lipid phases.
Non-lamellar prone lipids are able to modulate the physical
properties of biomembranes by inducing alterations in the
intrinsic curvature of the monolayer, in the lateral surface
pressure, and in the hydration of membranes [113]. Cell
membranes are usually rich in the non-lamellar prone, inverted
hexagonal (HII) phase inducing lipid phosphatidylethanolamine
(PE), which is mainly distributed on the inner side of the plasma
membrane [114] (i.e., the normal site for G protein binding).
The relative amount of PE in membranes under physiological
conditions is sufficient to provoke the formation of regions with
a negative curvature strain in vivo, which might be stabilized or
induced by the presence of particular membrane proteins [115].
Indeed, it has recently been shown that the greater the
hexagonal-phase propensity, the higher the affinity of hetero-
trimeric αi proteins for the membrane [116]. Therefore, PE-rich
domains or regions with negative curvature strain could act as a
membrane platform for these peripheral proteins, either as a
stable microdomain or as a dynamic transitory arrangement.
This concept is supported by the loss of G proteins from brain
plasma membranes observed after disruption of non-lamellar
HII structures by daunomycin [117].
Interestingly, GPCRs seem to display similar preferences to
heterotrimeric G proteins. It was proposed that lipids with a
negative spontaneous curvature favor elongation of the G-
protein-coupled photoreceptor rhodopsin during the activation
process. This was explained by the fact that they facilitated the
conformational change of rhodopsin to its activated state in
model membranes [118]. Moreover, measurements of the
interaction of this receptor and its corresponding G protein
transducin (αt) in lipid bilayers demonstrated that PE markedly
increased receptor affinity for αt upon light activation, while the
affinity of αt for dark-adapted rhodopsin remained unchanged
[119]. In contrast, in pure lamellar PC bilayers the affinity of αt
for light-activated rhodopsin was substantially lower. The
polyunsaturated docosahexaenoic acid (DHA) comprises
about 50% of the lipid fraction of retinal rod outer segment
membranes where rhodopsin is normally found, and this lipid
displays a strong tendency to induce curved structures [120].
Nevertheless, the observation that rhodopsin activation can also
be supported by other non-lamellar lipids, such as the
hexagonal-prone PE, indicates that it is more likely the physicalcurvature stress induced by these lipids than a direct lipid-
specific reaction between DHA and rhodopsin, which facilitates
the conformational change of this GPCR. It is noteworthy that
peptides with α-helical structures, such as the transmembrane
regions of GPCRs, promote the formation of hexagonal phases
under certain conditions in vitro [121]. In fact, a pronounced
restructuring of membrane lipids during photoactivation of
rhodopsin occurs, which provides strong evidence for the
dynamic interaction of this GPCR with the lipid phase of the
disc membranes [122]. It may be possible that upon agonist
activation the GPCRs themselves initiate the assembly of
microdomains with specific hexagonal-prone biophysical
characteristics around them and that the presence of non-
lamellar-prone membrane lipids is substantial for this conver-
sion of the receptor environment. Thus, hexagonal phase-
forming membrane lipids seem to fulfill a dual role in signal
transduction, by inducing the co-localization of the first
signaling components and by participating in GPCR activation.
In contrast to G protein heterotrimers, the activated mono-
meric αi-subunit showed a marked preference for pure lamellar
structures [116]. This would provoke the rapid exit of activated
αi-monomers from the receptor environment where the
hexagonal-phase propensity is increased. Mobilization of the
Gα protein subunit away from the receptor environment may
favor its interaction with effector proteins located in other
membrane domains (e.g., adenylyl cyclase). In fact, both αi and
αs have been found in lipid rafts [123]. Another study confirmed
that some G protein subunits did indeed co-localize with
adenylyl cyclase in lo membrane structures, in this case in
caveolae. However, most G proteins resided in irregular
structures of the plasma membrane, which could not be
morphologically identified [124]. When considered in conjunc-
tion with the finding that αt translocates to lipid rafts only upon
activation [125], it seems obvious that the opposite binding
preferences of activated Gα subunits indeed target them away
from the receptor surroundings to membrane sites where they
may efficiently interact with their effectors. This leads to amodel
where two spatially separated membrane areas have contrasting
biophysical properties, one harboring the pre-active G hetero-
trimer and the other, the activated Gα monomer. This idea is
further strengthened when considering that a considerable
number of signal transduction proteins are located in specialized
membrane sites, namely lipid rafts [126,127]. Thus, lipid rafts
appear to represent platforms whose specific biophysical
properties enhance the effectiveness of the second step of the
signaling cascade, trapping activated Gα subunits and augment-
ing the spatial proximity between them and their effectors.
On the other hand, dissociated Gβγ dimers still maintain a
high affinity for membranes with a hexagonal propensity [116],
which may also influence their distribution in native mem-
branes. The general observation that prenylated proteins are
normally not localized in lipid rafts [128] was also corroborated
for Gβγ subunits, which were found to be excluded from
synthetic lipid rafts [129]. This indicates that the Gβγ dimer
most probably determines the lipid–protein interaction char-
acteristics of the heterotrimeric G proteins. As such, the Gβγ
dimer defines the preference of complete Gαβγ heterotrimers
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brane affinity of the Gα-subunit. As a result, one of the
functions of the Gβγ dimer could be to shuttle the lamellar
membrane phase preferring Gα subunit to the vicinity of the
receptor, making it available for instant activation.
In this context, an interesting property has recently been
associated with the post-translational modification of Gγ
subunits with the isoprenyl moieties farnesol and geranylger-
aniol [130]. In model membranes containing PE, these
isoprenoids segregate in a multidomain system formed by a
lamellar crystalline (Lc) phase and isoprenoid aggregates. In
addition, they promoted a temperature-dependent growth of the
hexagonal phase that was able to coexist within the lamellar Lc
phase. Although the farnesol and geranylgeraniol used in this
study were free isoprenoids, a similar behavior was defined in
experiments with these isoprenyl moieties bound to the carboxy
terminal peptide of the Gγ2 subunit (manuscript in preparation,
P. Escribá). Consequently, it is possible that in vivo the Gβγ
dimer not only displays a preference for areas rich in non-
lamellar lipids, but that it is also actively involved in the
formation or maintenance of hexagonal-prone microdomains
with spontaneous negative curvature.
It is tempting to speculate that the preference of the Gβγ
dimer for hexagonal (HII) phases could well be important for
GPCR desensitization following agonist-mediated activation.
Dissociated Gβγ dimers can bind to G-protein-coupled receptor
kinases (GRKs), which phosphorylate and inactivate GPCRs.
The affinity of the Gβγ dimer for non-lamellar membrane
regions where the membrane receptors would also be located
could direct these kinases to their target, provoking the
termination of the signaling process initiated by binding of
the agonist to the receptor. This hypothesis is strongly supported
by the involvement of membrane lipids other than PC in the
regulation of GPCR phosphorylation and desensitization.
Indeed, with the exception of PC, membrane lipids can actually
regulate GRK activity [131]. Notably, the retinal GRK1 has a
farnesyl moiety covalently attached to its carboxy terminal
domain, similar to the Gβγ dimer. Moreover, the presence of
this isoprenoid group is essential for light-dependent membrane
association of GRK1 [132]. A mutant unfarnesylated form of
the kinase remained in the soluble fraction following light
exposure and displayed a reduced capacity to phosphorylate
rhodopsin. In contrast, a mutant kinase bearing a more
hydrophobic geranylgeranyl (C20) isoprenoid moiety was
constitutively associated with the membrane although it
phosphorylated rhodopsin at a rate comparable to wild-type
(farnesylated) GRK1 [132]. Thus, the specific modification
found in vivo (farnesylation) ensures that membrane association
of GRK1 only occurs in the presence of its activated receptor
substrate. However, GRK 4 and 6 are palmitoylated rather than
farnesylated [10,133], making it possible that these kinases are
regulated distinctly by different membrane lipids.
4.3.3. Interaction of membrane lipids with
phosphoinositide-specific phospholipases C
Phospholipases C (PLC) is an enzyme superfamily that is
widely distributed in bacteria and eukaryotes. These enzymescatalyze the cleavage of the P–O bond of a phosphoglyceride to
yield diacylglycerol (DAG) and a water-soluble phosphoryl
derivative (e.g., phosphorylcholine when the parent phospho-
glyceride is phosphatidylcholine). Phosphoinositide-specific
phospholipase C (PI-PLC) is particularly important because
both the end-products produced are potent metabolic signals,
phosphoinositols and DAG. PI-PLCs have received special
attention in eukaryotes because of their implication in signal
transduction. However, several members of the Bacillus and
Listeria genera contain PI-PLC that is structurally simpler
while maintaining the activity of their mammalian counterparts.
Hence, a number of relevant studies have been carried out on
these bacterial isozymes. In all cases, the substrates of these
enzymes comprise a part of the lipid bilayer and thus, PLCs
must interact with the membrane even though such interactions
are mostly transient. PLCs usually belong to the group of the so-
called “non-permanent membrane proteins” [134], and they
pertain to the subgroup of proteins that interact reversibly with
the membrane and cause the covalent modification of the lipids.
4.3.3.1. Studies with Bacillus PI-PLC. An important break-
through in the field of bacterial PLCs was the elucidation of the
crystal structure and the proposal of a mode of action for the
Bacillus enzyme. The crystal structure of the PI-specific PLC
from B. cereus in a complex with myo-inositol was resolved at a
resolution of 2.3 Å by Heinz et al. [135]. The structure consists
of an imperfect (β α)8-barrel similar to that first observed for the
triose phosphate isomerase. Myo-inositol, a substrate-like
inhibitor, interacts with His 32 and His 82, two highly
conserved residues in bacterial and eukaryotic PLCs. The
involvement of these residues suggested their role in a general
acid–base catalytic mechanism of the kind observed for
ribonucleases, a hypothesis that received experimental support
[136–138]. From these studies, a mechanism emerged by which
PI-PLC could catalyze the cleavage of the P–O bond in PI
through intramolecular nucleophilic attack of the axial 2-OH
group of inositol on the P atom. The catalytic site of PI-PLC
would accordingly consist of three main components: His 32
general base; His 82 general acid; and Arg 69 acting as a
phosphate-activating residue (Fig. 1).
PI-PLC binding to lipid bilayers has been widely studied in
various laboratories. Studies of the interfacial binding of PI-PLC
from B. thuringiensis (whose sequence is very similar to that of
the homologous B. cereus enzyme) led to the proposal of a two-
stage binding model [139–141]. According to this model, the
protein would first bind to the bilayer surface through
electrostatic forces and it would only then form a tight membrane
protein complex stabilized by hydrophobic forces. In this
context, it is relevant that PI-PLC contains two Trp residues (Trp
47 and Trp 242 for the B. thurigiensis enzyme) that are common
to other membrane proteins and that play a role in lipid binding
[142]. A correlation between PI-PLC binding to the phospho-
lipid–water interface, as well as changes in Trp fluorescence
emission and catalytic activity have also been observed [143].
One interesting feature of Bacillus PI-PLCs is their
sensitivity to lipids other than their substrate, particularly PC.
This phospholipid augments the affinity of PI-PLC for its
Fig. 1. Reaction mechanism of PI-PLC involving the general acid-general base
histidine residues that must be precisely positioned for efficient catalysis. A Ca2+
ion (not shown) is involved in stabilizing the phosphonate formation by
interacting with the oxygen molecules (OR and OS) during formation of the
intermediate (2). The reaction is completed by hydrolysis (3) and finally the
product is formed (4). [Reprinted with permission from Biochemistry 2005, 44,
9980–9. Copyright 2005 American Chemical Society].
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accordance with which PI-PLC would specifically bind to PC
[144–146]. In addition to the catalytic site and the allosteric
binding site(s), it is proposed that the enzyme would possess an
interface binding surface (or i-face), similar to other interface-
acting enzymes. It has been proposed that the interface binding
event would be different from the catalytic event [147],
although the two may be allosterically coupled. The effect of
a variety of non-substrate lipids on the PI-PLC activity has been
examined, including that of PC, PE, sphingomyelin, galacto-
sylceramide and cholesterol [148]. Simultaneous measurements
of enzyme activity, interfacial enzyme binding, and the
fluorescence of different probes, reveal that both enzyme
binding and activity diminish with increasing lipid order
(decreasing fluidity). These results support a “two-stage
model” for binding of PI-PLC to lipid bilayers, and underline
the significance of the partial penetration of the enzyme into the
membrane's hydrophobic matrix for its catalytic activity.
The catalytic activity of phosphatidylcholine-preferring PLC
(PC-PLC) from B. cereus induced the aggregation and fusion of
large unilamellar vesicles containing PC, PE, and cholesterol
[149]. Subsequently, a similar phenomenon induced by B.
cereus PI-PLC was described in vesicles containing PI, neutral
phospholipids, and cholesterol [150]. In both cases, the enzyme
end-product diacylglycerol is the essential fusogenic agent.
Indeed, vesicle–vesicle fusion was then shown to be limited by
the frequency of contact between two diacylglycerol-rich
domains [151] (a review on PLC-induced membrane fusion
can be found in Goñi and Alonso [152]). Various lines of
evidence suggest that PLC-induced fusion may be relevant to
the in vivo situation. Phospholipases C and diacylglycerol are
involved in exocytosis [153,154] and in the acrosome reaction
of spermatozoa [155–158]. Diacylglycerol and its formation by
phospholipase C also appear to regulate Rab- and SNARE-
dependent yeast vacuole fusion [159]. Moreover, if we interpretbudding and fission as processes that are the mirror image of
fusion, the constant pool of diacylglycerol required by Golgi
membranes for the generation of secretory vesicles becomes
more noteworthy ([160]; for a review see [161]).
4.3.3.2. Studies with eukaryotic PI-PLCs. By far the most
detailed studies on eukaryotic PI-PLCs have been carried out in
mammals and thus, with a few exceptions mentioned below, this
section will deal essentially with these mammalian PI-PLCs.
There are about a dozen known mammalian PI-PLC isoforms
that are divided into six groups, namely β, γ, δ, ε, ζ, and η. The
PLCβ isoforms are the major PLC isoforms involved in GPCR-
mediated calcium signaling, which can also control the cell
cycle, while the PLCγ isoforms are the PLC isoforms coupled
to tyrosine kinase receptors, such as the EGF and PDGF
receptors, and receptors associated with tyrosine kinases, such
as the T cell and B cell receptors [162,163]. PLCδ is a potential
amplifier of Ca++ signals [164]. What is known of the more
recently discovered groups, PLCε is an effector of Ras and other
GTP-binding proteins [165], PLCζ is extremely sensitive to
intracellular Ca2+ concentrations [166], and PLCη is implicated
in neuronal activity [167].
Virtually all mammalian PLCs contain: (i) the so-called X
and Y domains, which form the catalytic core, (ii) an N-terminal
Pleckstrin homology (PH) domain, (iii) four EF-hand domains;
and (iv) a C-terminal C2 domain [167]. The catalytic core has a
triose-phosphate isomerase-like barrel structure, the same
structure that is found in the single-Bacillus PI-PLC domain
[135]. One or more of these domains interact with the
membrane lipid–water interface during catalysis. Like the Ba-
cillus and other bacterial isoforms, mammalian PLCs cleave the
P–O bond via trans-esterification, using the axial OH group of
the inositol ring as a nucleophile. Accordingly, they generate a
five-membered cyclic phosphate as an intermediate or some-
times as a final product (Fig. 1), and the different enzymes
release distinct proportions of the cyclic and the linear
phosphate products. The reaction mechanism requires a general
acid–base system to facilitate proton transfer, and a positively
charged species central to the acid–base pair to promote
formation of the transition state phosphate species. The acid–
base pair is provided by two essential His residues at the active
site. The positively charged species is a Ca2+ ion in mammalian
and in a few bacterial enzymes, while most other bacterial
isoforms utilize a guanidinium group from a neighboring Arg
residue [168–170].
The membrane interactions of mammalian PI-PLCs have
been particularly well studied in the case of PLCδ1, whose PH
domain has been cloned and its membrane activity analyzed.
PH domains are about 120 aa, and they are frequently found in
proteins involved in cell signaling and cytoskeletal functions.
Inositol lipids are important ligands of PH domains [171–174].
The PH domains from different proteins exhibit rather low
sequence similarity, but their secondary and tertiary structural
motifs are highly conserved. A high-resolution structural model
of the rat PLCδ1 PH domain forming a complex with Ins(1,4,5)
P3 has been determined by X-ray diffraction. In this model, the
PH domain was proposed to form a seven-stranded β sandwich
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terminal amphipathic α-helix [175]. At least in the case of
PLC-δ1, the interaction with PI-4,5-bisphosphate occurs mainly
through the loops connecting β1/β2 and β3/β4. In turn, the
β5/β6 loop includes a short amphipathic α-helix, the α2-helix,
which is not found in other PH domains studied so far.
The conformational changes induced in the PLCδ1 PH
domain upon interaction with a lipid bilayer were first described
using solid state NMR [176]. Upon interacting with a lipid
bilayer composed of phosphatidylcholine and phosphatidylino-
sitol-4,5-bisphosphate, a local conformational change occurred
in the β5/β6 loop mentioned above. According to the NMR
data, the short amphipathic α-helix in this loop interacts with
the hydrophobic membrane matrix, thus contributing to the
membrane binding affinity, as well as the interdomain and
intermolecular interactions of PLCδ1.
A further step in characterizing the interaction of the PH
domain with membranes was made by using an isolated
recombinant PH domain in studies with lipid monolayers and
vesicles [177]. The PH domain from PLCδ1 (PH-PLCδ1)
displays two modes of membrane binding: (i) a reversible one,
that involves the specific recognition of the PI head group, and
that does not include membrane penetration; and (ii) a long-
lived one that involves membrane insertion promoted by
phosphatidylethanolamine and cholesterol, that does not require
occupation of the PI-binding site. The long-lived activity of PH-
PLCδ1 is not observed in other PH modules. It is unclear which
parts of PH-PLCδ1 are responsible for its membrane insertion
activity although on the basis of prior studies [178], it was
suggested that the major contribution to membrane activity
comes from superficial hydrophobic residues in the C-terminal
portion of PH [177]. Non-specific binding of PH domains to
membranes has also been found in PLCβ-PH domains [179].
Molecular modeling studies of all mammalian PLC PH domains
[180] point to striking differences in the electrostatic profiles of
these PH domains when compared to non-PLC PH domains, as
well as to the role of non-specific electrostatic interactions in the
membrane localization of the PLCδ-, PLCγ-, and PLCβ-PH
domains.
The PH domains of PLCγ target membranes containing PI-
3,4,5-trisphosphate, in contrast to the affinity of the PLCδ-PH
domain for PI-4,5-bisphosphate [181]. In addition, PLCγ can
bind to lipid bilayers via a different mechanism, namely the
formation of an intermolecular lipid-binding domain with a
canonical transient receptor potential 3 (TRPC3) ion channel
[163]. The latter are receptor-operated Ca2+ channels, such that
formation of the intermolecular lipid-binding domain allows
PLCγ to regulate Ca2+ entry in the cell. Interestingly, PLCγ has
a split PH domain whose C-terminal half (cPH) could give rise
to a functional PH-like intermolecular domain when it interacts
with TRPC3. A non-canonical PH domain has been predicted
within the N terminus of TRPC3 that corresponds to the actual
PLCγ-cPH binding pocket [182]. Moreover, in vitro experi-
ments show that TRPC3 binds to PI-4,5-bisphosphate only in
the presence of PLCγ-cPH. However, it remains to be
established whether the PLCγ-cPH/TRPC3 complex does
indeed adopt the structure of an intermolecular PH domain, orwhether it constitutes a different functionally analogous lipid-
binding domain [183].
Although the PH domain appears to be very important for
PLC–membrane interactions, other protein domains are also
important. Indeed, the EF3 and EF4 motifs of the EF-hand
domain are involved in enzyme binding to free fatty acids [184].
While these experiments were performed with the lipid-
detergent form of the substrate in mixed micelles, it is likely
that EF3 and EF4 are also involved in the enzyme interaction
with the phospholipid fatty acyl chains in the bilayer
environment. It is noteworthy that the newly described PLCη
does not have a PH domain [167] and hence, studies of PLCη–
membrane interactions should provide valuable information in
this regard.
4.3.4. Interaction of membrane lipids with protein kinase C
isoforms
Certain GPCRs use phospholipase C as an effector of
signaling, this enzyme producing diacylglycerol (DAG) and
inositol phosphate as second messengers. DAG induces
activation of protein kinase C (PKC) through both specific
lipid–protein interactions and through the induction of non-
lamellar phases [185]. Therefore, PKC acts as third messenger
in the GPCR cascade, propagating messages from the
membrane to the cytosol or other cellular compartments. Non-
lamellar phase (HII) propensity has been shown to be involved
in the translocation of PKC from the cytosol to membranes, a
phenomenon associated with enzyme activation [117,186].
Therefore, membrane protein–lipid interactions regulate the
first signaling steps initiated through GPCRs: receptors, G
proteins, effectors/second messengers and some third messen-
gers. Obviously, other processes involving the interaction of
further messengers with internal membranes may also be
regulated by these interactions.
PKC isozymes form a family of proteins involved in several
signaling pathways [187]. The interaction of conventional PKCs
(α, β and γ) with membranes is not only modulated by DAG
and phorbol esters, but it is also under the influence of Ca2+
(another second messenger) and phosphatidylserine, one of the
main lipids in the cytosolic leaflet of the plasma membrane.
Although some studies suggest a specific interaction between
PKC with phosphatidylserine [188], other studies indicate that
other anionic phospholipids can substitute for this lipid [189]. In
any case, PKC activation depends on the presence of a negative
charge at the interface region of the membrane. In addition to
DAG another non-lamellar prone phospholipid that is abundant
in the inner leaflet of the cell membrane, phosphatidylethano-
lamine (PE), also facilitates the association of PKC with
membranes [117,186]. The exact details of the interaction
between PKC and membranes with hexagonal-prone lipids are
still to be elucidated, but a growing body of evidence points to
the possibility that the tendency of a negative curvature to
provoke a splayed configuration of phospholipids (see Section
4.2) could be a key property. This may reflect the fact that some
phospholipids may extend one of their phospholipid acyl chains
out of the membrane when the lateral pressure is high, as in the
case of membranes with strong hexagonal propensity, in order
847P.V. Escribá et al. / Biochimica et Biophysica Acta 1768 (2007) 836–852to relieve some of the pressure [95]. Calcium ions are also
required for PKC translocation and activation and they consume
water at the membrane surface for their own hydration. This
leads to the dehydration of the membrane surface which further
augments the curvature stress [190] and as a consequence, the
formation of a splayed phospholipid configuration. None-
theless, from an energetic viewpoint a single hydrophobic acyl
chain in an aqueous environment is not a very favorable
arrangement. The high positive energy of such a position would
be largely reduced if a protein could cover the extended acyl
chain with a hydrophobic pocket. This would also provide an
anchoring point for transiently bound membrane proteins.
Indeed, protein kinase C contains such a hydrophobic pocket
[191]. Accordingly, it is the non-lamellar phase propensity (or
the membrane curvature strain) more than a specific interaction
between PE and the enzyme that participates in the membrane
recruitment of PKC, both in model and cell membranes. Finally,
the number of double bonds of the acyl chains of membrane
phospholipids (the degree of unsaturation) also markedly
influences PKC activity [192]. However, PE, cholesterol and
the size of the liposomes are also able to alter PKC activity.
Therefore, it seems that the head group spacing of the
membrane phospholipids, a parameter closely related to
intrinsic bilayer curvature, mainly governs the ability of PKC
to interact with the membrane rather than the lipid acyl chain
order.
In general, the wide variety in the composition of cell
membranes from the different cell types found in an organism
suggests that PKC will display diverse interactions with the
membrane (and other peripheral proteins). Moreover, the
variety of domains and microdomains in cell membranes
implies that lipids may also regulate its location and activity,
independent of receptors for activated C kinase (RACK)
proteins [186]. In this context, an increase of the non-lamellar
phase propensity of membranes favors the binding of purified
membrane proteins to model membranes in the absence of
other external factors, demonstrating that the cellular localiza-
tion of PKC is not only regulated by RACK proteins. In living
cells, modest HII inducers result in a mild increase in PKC
activity, with a persistent increase of PKC expression [186]. In
contrast, strong HII inducers (e.g., phorbol esters) result in
exaggerated PKC activation followed by enzyme depletion.
Membrane lipids may be altered as a consequence of a
pathological state [193], dietary fat intake [194], or physiolo-
gical situations [195]. These include alterations in the
membrane concentration of phospholipids classes, the degree
of unsaturation of the fatty acyl chains, cholesterol levels, etc.,
and they have been shown to regulate PKC-membrane lipid
interactions and thus, PKC activity [196]. In this context, it is
conceivable that inducing changes in the membrane lipid
composition through drug treatments aimed at regulating PKC
or other membrane proteins may reverse a pathological state.
This clinical approach has been termed “membrane lipid
therapy” [193]. Indeed, minerval (2-hydroxy-9-cis-octadece-
noic acid) regulates the membrane structure and the localiza-
tion and activity of PKC, triggering a series of events associated
with its antitumoral action.5. Conclusion and future perspectives
In spite of the multitude of physical and biochemical
influences constantly interfering with lipid bilayer integrity,
membrane lipid composition of biomembranes remains amaz-
ingly stable. The answer to the question why their composition
is so precisely regulated, is simple. Lipids are equally important
for biological processes, because they are functionally relevant
for the correct and efficient response of membrane proteins to
extra- and intracellular stimuli. The fact, that a great part of
GPCR-associated signaling takes part in or at the plasma
membrane already suggests a great importance for lipid–protein
interactions. This review shows the variety of possible
interactions, starting with co- or post-translational lipid
modifications of key signaling proteins, continuing with the
effect of membrane lipid structure and bilayer organization on
affinity and localization of signaling proteins, and ending with
the direct interaction of specific membrane lipids and effector
enzymes. Considering this and the fact that G-protein-coupled
signaling proteins form the major target group for pharmaceu-
tical drugs today, it becomes apparent that manipulation of
membrane lipid composition might be similarly used in the
treatment of diseases. In fact, the nutritional influence of special
diets or their components (e.g., the Mediterranean diet or olive
oil) showed beneficial effects on the onset or progression of a
variety of illnesses while at the same time modifying plasma
membrane lipid composition [197–200]. However, it remains to
be seen whether the development of drugs aiming to alter lipid–
protein interaction will become an equally valuable therapeu-
tical strategy in the future as the classical approach directed
against proteins.
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